New Insights in Type I and II CD20 Antibody Mechanisms-Of-Action With a Panel of Novel CD20 Antibodies

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.15132
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Phase I Study of Chimeric Anti-Cd20 Monoclonal Antibody in Chinese Patients With CD20-positive Non-Hodgkin’s Lymphoma

Chinese Journal of Cancer Research
Cancer ResearchOncology
2016English

Cellular Cytotoxicity of Next Generation CD20 Monoclonal Antibodies

Cancer immunology research
Cancer ResearchImmunology
2018English

Inhibition of Increased Circulating TFH Cell by Anti-Cd20 Monoclonal Antibody in Patients With Type 1 Diabetes

PLoS ONE
Multidisciplinary
2013English

Secondary Antibody Deficiency: A Complication of Anti-Cd20 Therapy for Neuroinflammation

Journal of Neurology
Neurology
2018English

Characterization of Novel Murine Anti-Cd20 Monoclonal Antibodies and Their Comparison to 2B8 and C2B8 (Rituximab)

International Journal of Oncology
Cancer ResearchOncology
2007English

Comment on “Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells”

Journal of Immunology
AllergyImmunology
2018English

Molecular Mechanisms of B Lymphocyte Depletion by CD20 Immunotherapy

Japanese Journal of Clinical Immunology
2009English

Antibodies to CD20 and MHC Class II Antigen Bound to B-Lymphoma Cells Accumulate in Shed Cytoplasmic Fragments

British Journal of Cancer
Cancer ResearchOncology
2004English

Antibody-Targeted Paclitaxel Loaded Nanoparticles for the Treatment of CD20+ B-Cell Lymphoma

Scientific Reports
Multidisciplinary
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy